See All Slides - tctmd.com

Slides

Presentation TCT 2013

2 Case Vignettes in Non-left Main Provisional Stenting: Only 1 Stent Needed

Presenter: Thierry Lefevre

October 28, 2013

Presentation TCT 2013

Learning Curve and Volume Requirements

Presenter: Asim Cheema

October 28, 2013

Presentation TCT 2013

Editorial Comment: Anatomical and Clinical Considerations for Transcatheter Mitral Valve Repair

Presenter: Francesco Maisano

October 28, 2013

Presentation TCT 2013

Effective Dashboards to Drive Quality Changes

Presenter: Judy Tingley

October 28, 2013

Presentation TCT 2013

Risk/Benefit Favors: Medical Therapy First

Presenter: David Maron

October 28, 2013

Presentation TCT 2013

Epidemiology and Prognostic Impact of Mitral Regurgitation (and Why Does MR Take a Backseat to Aortic Stenosis?)

Presenter: Maurice Sarano

October 28, 2013

Presentation TCT 2013

The Claret Montage Dual Filter Device: Pathoanatomic Findings from Filtered Debris after TAVR

Presenter: Nicolas van Mieghem

October 28, 2013

Presentation TCT 2013

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

Presenter: Laura Mauri

October 28, 2013

Presentation TCT 2013

A Preview of the Extreme Risk US CoreValve Registry

Presenter: Jeffrey Popma

October 28, 2013

Presentation TCT 2013

Yes! The Multicenter Registry Data Are Compelling

Presenter: Nicolas van Mieghem

October 28, 2013

Advertisement

Slides

2 Case Vignettes in Non-left Main Provisional Stenting: Only 1 Stent Needed

Learning Curve and Volume Requirements

Editorial Comment: Anatomical and Clinical Considerations for Transcatheter Mitral Valve Repair

Effective Dashboards to Drive Quality Changes

Risk/Benefit Favors: Medical Therapy First

Epidemiology and Prognostic Impact of Mitral Regurgitation (and Why Does MR Take a Backseat to Aortic Stenosis?)

The Claret Montage Dual Filter Device: Pathoanatomic Findings from Filtered Debris after TAVR

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

A Preview of the Extreme Risk US CoreValve Registry

Yes! The Multicenter Registry Data Are Compelling

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content